Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma

Proteomics

Volumn 15, Issue 2-3, 2015, Pages 383-393

  Syed, Nazia ^a,b   Chavan, Sandip ^a,c   Sahasrabuddhe, Nandini A ^a   Renuse, Santosh ^a,d   Sathe, Gajanan ^a,c   Nanjappa, Vishalakshi ^a,d   Radhakrishnan, Aneesha ^a,b   Raja, Remya ^a   Pinto, Sneha M ^a,c   Srinivasan, Anand ^e   Prasad, T S Keshava ^a,d   Srikumar, Kotteazeth ^b   Gowda, Harsha ^a   Santosh, Vani ^f   Sidransky, David ^g   Califano, Joseph A ^g,h   Pandey, Akhilesh ^g   Chatterjee, Aditi ^a  

^a INSTITUTE OF BIOINFORMATICS   (India)

^b PONDICHERRY UNIVERSITY   (India)

^c MANIPAL UNIVERSITY   (India)

^d AMRITA UNIVERSITY   (India)

^e POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^f NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h GREATER BALTIMORE MEDICAL CENTER   (United States)

Author keywords

Antimetabolite; Biomarker; Biomedicine; Drug resistance; In vitro labeling

Indexed keywords

CALPASTATIN; CISPLATIN; CLAUDIN 7; EZRIN; FLUOROURACIL; HIGH MOBILITY GROUP A1A PROTEIN; HIGH MOBILITY GROUP B2 PROTEIN; MESSENGER RNA; MIDKINE; SMALL INTERFERING RNA; SOMATOMEDIN B; ANTINEOPLASTIC AGENT;

ARTICLE; CONTROLLED STUDY; DNA REPAIR; DNA REPLICATION; DNA STRUCTURE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KERATINOCYTE; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DNA BINDING; TANDEM MASS SPECTROMETRY; TISSUE MICROARRAY; WESTERN BLOTTING; CARCINOMA, SQUAMOUS CELL; CELL LINE; DRUG RESISTANCE; GENETICS; HEAD AND NECK NEOPLASMS; PATHOLOGY; PROTEOMICS; RNA INTERFERENCE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HMGB2 PROTEIN; HUMANS; PROTEOMICS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TANDEM MASS SPECTROMETRY;

EID: 84921313925     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201400338     Document Type: Article

References (69)

1. Leemans, C. R., Braakhuis, B. J., Brakenhoff, R. H., The molecular biology of head and neck cancer. Nat. Rev. Cancer 2011, 11, 9-22.
2. Yarbrough, W. G., Slebos, R. J., Liebler, D., Proteomics: clinical applications for head and neck squamous cell carcinoma. Head & Neck 2006, 28, 549-558.
3. Matta, A., Ralhan, R., DeSouza, L. V., Siu, K. W., Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery. Mass Spectrom. Rev. 2010, 29, 945-961.
4. Marimuthu, A., Chavan, S., Sathe, G., Sahasrabuddhe, N. A. et al., Identification of head and neck squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell secretome. Biochim. Biophys. Acta 2013, 1834, 2308-2316.
5. Sepiashvili, L., Hui, A., Ignatchenko, V., Shi, W. et al., Potentially novel candidate biomarkers for head and neck squamous cell carcinoma identified using an integrated cell line-based discovery strategy. Mol. Cell. Proteomics 2012, 11, 1404-1415.
6. Wang, W., Jiang, H., Zhu, H., Zhang, H. et al., Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma. Oncol. Lett. 2013, 5, 884-888.
7. Sharma, A., Ray, R., Rajeswari, M. R., Overexpression of high mobility group (HMG) B1 and B2 proteins directly correlates with the progression of squamous cell carcinoma in skin. Cancer Invest. 2008, 26, 843-851.
8. Kwon, J. H., Kim, J., Park, J. Y., Hong, S. M. et al., Overexpression of high-mobility group box 2 is associated with tumor aggressiveness and prognosis of hepatocellular carcinoma. Clin. Cancer Res. 2010, 16, 5511-5521.
9. Ouellet, V., Le Page, C., Guyot, M. C., Lussier, C. et al., SET complex in serous epithelial ovarian cancer. Int. J. Cancer 2006, 119, 2119-2126.
10. Nishio, M., Arioka, H., Nishio, K., Kubota, N. et al., Overexpression of cisplatin-inducible proteins that are recognized by anti-HMG antibody in cisplatin-resistant human lung cancer cell lines. Colloids Surf. B 1994, 1, 251-255.
11. Pendleton, K. P., Grandis, J. R., Cisplatin-based chemotherapy options for recurrent and/or metastatic squamous cell cancer of the head and neck. Clin. Med. Insights Ther. 2013, 2013.
12. Longley, D. B., Harkin, D. P., Johnston, P. G., 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 2003, 3, 330-338.
13. Morton, R. P., Rugman, F., Dorman, E. B., Stoney, P. J. et al., Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother. Pharmacol. 1985, 15, 283-289.
14. Lebwohl, D., Canetta, R., Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur. J. Cancer 1998, 34, 1522-1534.
15. Kelland, L., The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 2007, 7, 573-584.
16. Wang, D., Lippard, S. J., Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 2005, 4, 307-320.
17. Siddik, Z. H., Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22, 7265-7279.
18. Huang, J. C., Zamble, D. B., Reardon, J. T., Lippard, S. J., Sancar, A., HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc. Natl. Acad. Sci. USA 1994, 91, 10394-10398.
19. Damia, G., Filiberti, L., Vikhanskaya, F., Carrassa, L. et al., Cisplatinum and taxol induce different patterns of p53 phosphorylation. Neoplasia 2001, 3, 10-16.
20. Wang, Z., Wu, X., Friedberg, E. C., Nucleotide-excision repair of DNA in cell-free extracts of the yeast Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 1993, 90, 4907-4911.
21. Andreadis, C., Vahtsevanos, K., Sidiras, T., Thomaidis, I. et al., 5-Fluorouracil and cisplatin in the treatment of advanced oral cancer. Oral Oncology 2003, 39, 380-385.
22. Vokes, E. E., Brockstein, B. E., Humerickhouse, R., Haraf, D. J., Oral 5-FU alternatives for the treatment of head and neck cancer. Oncology (Williston Park) 1998, 12, 35-38.
23. Jacobs, C., Lyman, G., Velez-Garcia, E., Sridhar, K. S. et al., A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol. 1992, 10, 257-263.
24. Lehman, N. L., Future potential of thymidylate synthase inhibitors in cancer therapy. Expert Opin. Investig. Drugs 2002, 11, 1775-1787.
25. Venugopal, A. K., Ghantasala, S. S., Selvan, L. D., Mahadevan, A. et al., Quantitative proteomics for identifying biomarkers for Rabies. Clin. Proteomics 2013, 10, 3.
26. Rappsilber, J., Mann, M., Ishihama, Y., Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat. Protoc. 2007, 2, 1896-1906.
27. Kandasamy, K., Pandey, A., Molina, H., Evaluation of several MS/MS search algorithms for analysis of spectra derived from electron transfer dissociation experiments. Anal. Chem. 2009, 81, 7170-7180.
28. Goel, R., Muthusamy, B., Pandey, A., Prasad, T. S., Human protein reference database and human proteinpedia as discovery resources for molecular biotechnology. Mol. Biotechnol. 2011, 48, 87-95.
29. Muthusamy, B., Thomas, J. K., Prasad, T. S., Pandey, A., Access guide to human proteinpedia. Curr. Protoc. Bioinformatics 2013, Chapter 1, Unit 1 21.
30. Hermjakob, H., Apweiler, R., The Proteomics Identifications Database (PRIDE) and the ProteomExchange Consortium: making proteomics data accessible. Expert Rev. Proteomics 2006, 3, 1-3.
31. Mathivanan, S., Ahmed, M., Ahn, N. G., Alexandre, H. et al., Human Proteinpedia enables sharing of human protein data. Nat. Biotechnol. 2008, 26, 164-167.
32. Pawar, H., Maharudraiah, J., Kashyap, M. K., Sharma, J. et al., Downregulation of cornulin in esophageal squamous cell carcinoma. Acta Histochem. 2013, 115, 89-99.
33. Sen, T., Chang, X., Sidransky, D., Chatterjee, A., Regulation of DeltaNp63alpha by NFkappaBeta. Cell Cycle 2010, 9, 4841-4847.
34. Chatterjee, A., Mambo, E., Zhang, Y., Deweese, T., Sidransky, D., Targeting of mutant hogg1 in mammalian mitochondria and nucleus: effect on cellular survival upon oxidative stress. BMC Cancer 2006, 6, 235.
35. Madan, R., Brandwein-Gensler, M., Schlecht, N. F., Elias, K. et al., Differential tissue and subcellular expressionof ERM proteins in normal and malignant tissues: cytoplasmic ezrin expression has prognostic signficance for head and neck squamous cell carcinoma. Head & Neck 2006, 28, 1018-1027.
36. Moilanen, J., Lassus, H., Leminen, A., Vaheri, A. et al., Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients. Gynecol. Oncol. 2003, 90, 273-281.
37. Ma, L., Liu, Y. P., Zhang, X. H., Geng, C. Z., Li, Z. H., Relationship of RhoA signaling activity with ezrin expression and its significance in the prognosis for breast cancer patients. Chin. Med. J. 2013, 126, 242-247.
38. Patara, M., Santos, E. M., Coudry Rde, A., Soares, F. A. et al., Ezrin expression as a prognostic marker in colorectal adenocarcinoma. Pathol. Oncol. Res. 2011, 17, 827-833.
39. Lee, H. W., Kim, E. H., Oh, M. H., Clinicopathologic implication of ezrin expression in non-small cell lung cancer. Korean J. Pathol. 2012, 46, 470-477.
40. Xie, J. J., Xu, L. Y., Wu, Z. Y., Zhao, Q. et al., Prognostic implication of ezrin expression in esophageal squamous cell carcinoma. J. Surg. Oncol. 2011, 104, 538-543.
41. Muramatsu, T., Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J. Biochem. 2002, 132, 359-371.
42. Kato, M., Shinozawa, T., Kato, S., Awaya, A., Terada, T., Increased midkine expression in hepatocellular carcinoma. Arch. Pathol. Lab. Med. 2000, 124, 848-852.
43. Choudhuri, R., Zhang, H. T., Donnini, S., Ziche, M., Bicknell, R., An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res. 1997, 57, 1814-1819.
44. Jham, B. C., Costa, N. L., Silva, J. M., de Miranda, A. C. et al., Midkine expression in oral squamous cell carcinoma and leukoplakia. J. Oral Pathol. Med. 2012, 41, 21-26.
45. Ota, T., Ota, K., Jono, H., Fujimori, H. et al., Midkine expression in malignant salivary gland tumors and its role in tumor angiogenesis. Oral Oncol. 2010, 46, 657-661.
46. Ota, K., Fujimori, H., Ueda, M., Shiniriki, S. et al., Midkine as a prognostic biomarker in oral squamous cell carcinoma. Br. J. Cancer 2008, 99, 655-662.
47. Cristobal, I., Garcia-Orti, L., Cirauqui, C., Cortes-Lavaud, X. et al., Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica 2012, 97, 543-550.
48. Jiang, Q., Zhang, C., Zhu, J., Chen, Q., Chen, Y., The set gene is a potential oncogene in human colorectal adenocarcinoma and oral squamous cell carcinoma. Mol. Med. Rep. 2011, 4, 993-999.
49. Bell, J. L., Wachter, K., Muhleck, B., Pazaitis, N. et al., Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? Cell. Mol. Life Sci. 2013, 70, 2657-2675.
50. Mongroo, P. S., Noubissi, F. K., Cuatrecasas, M., Kalabis, J. et al., IMP-1 displays cross-talk with K-Ras and modulates colon cancer cell survival through the novel proapoptotic protein CYFIP2. Cancer Res. 2011, 71, 2172-2182.
51. Clauditz, T. S., Wang, C. J., Gontarewicz, A., Blessmann, M. et al., Expression of insulin-like growth factor II mRNA-binding protein 3 in squamous cell carcinomas of the head and neck. J. Oral Pathol. Med. 2013, 42, 125-132.
52. Lin, C. Y., Chen, S. T., Jeng, Y. M., Yeh, C. C. et al., Insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor formation and invasion and predicts poor prognosis in oral squamous cell carcinoma. J. Oral Pathol. Med. 2011, 40, 699-705.
53. Iyama, T., Wilson, D. M., 3rd, DNA repair mechanisms in dividing and non-dividing cells. DNA Repair (Amst.) 2013, 12, 620-636.
54. Lonning, P. E., Knappskog, S., Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. Oncogene 2013, 32, 5315-5330.
55. Lotze, M. T., Tracey, K. J., High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 2005, 5, 331-342.
56. Muller, S., Scaffidi, P., Degryse, B., Bonaldi, T. et al., New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J. 2001, 20, 4337-4340.
57. Dong Xda, E., Ito, N., Lotze, M. T., Demarco, R. A. et al., High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J. Immunother. 2007, 30, 596-606.
58. Ellerman, J. E., Brown, C. K., de Vera, M., Zeh, H. J. et al., Masquerader: high mobility group box-1 and cancer. Clinical Cancer Res. 2007, 13, 2836-2848.
59. Yamoah, K., Brebene, A., Baliram, R., Inagaki, K. et al., High-mobility group box proteins modulate tumor necrosis factor-alpha expression in osteoclastogenesis via a novel deoxyribonucleic acid sequence. Mol. Endocrinol. 2008, 22, 1141-1153.
60. Pusterla, T., de Marchis, F., Palumbo, R., Bianchi, M. E., High mobility group B2 is secreted by myeloid cells and has mitogenic and chemoattractant activities similar to high mobility group B1. Autoimmunity 2009, 42, 308-310.
61. Krynetskaia, N. F., Phadke, M. S., Jadhav, S. H., Krynetskiy, E. Y., Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol. Cancer Ther. 2009, 8, 864-872.
62. Varma, R. R., Hector, S. M., Clark, K., Greco, W. R. et al., Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10. Oncol. Rep. 2005, 14, 925-932.
63. Sharma, A., Ramanjaneyulu, A., Ray, R., Rajeswari, M. R., Involvement of high mobility group B proteins in cisplatin-induced cytotoxicity in squamous cell carcinoma of skin. DNA Cell Biol. 2009, 28, 311-318.
64. Wu, Z. B., Cai, L., Lin, S. J., Xiong, Z. K. et al., High-mobility group box 2 is associated with prognosis of glioblastoma by promoting cell viability, invasion, and chemotherapeutic resistance. Neuro Oncol. 2013, 15, 1264-1275.
65. Shin, Y. J., Kim, M. S., Lee, J., Kang, M., Jeong, J. H., High-mobility group box 2 (HMGB2) modulates radioresponse and is downregulated by p53 in colorectal cancer cell. Cancer Biol. Ther. 2013, 14, 213-221.
66. Price, K. A., Cohen, E. E., Current treatment options for metastatic head and neck cancer. Curr. Treat. Options Oncol. 2012, 13, 35-46.
67. Zlatanova, J., Yaneva, J., Leuba, S. H., Proteins that specifically recognize cisplatin-damaged DNA: a clue to anticancer activity of cisplatin. FASEB J. 1998, 12, 791-799.
68. Kartalou, M., Essigmann, J. M., Mechanisms of resistance to cisplatin. Mutat. Res. 2001, 478, 23-43.
69. Vizcaíno, J. A., Côté, R. G., Csordas, A., Dianes, J. A. et al., The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res. 2013, 41, D1063-1069.